Posted in Web Chasing Amgen on KRAS combo, Roche dishes out $75M for … February 11, 2021 Roche’s money is on a combination of RLY-1971 and GDC-6036, its Phase I drug, for patients with KRAS G12C mutant tumors. James Sabry https://endpts.com/chasing-amgen-on-kras-combo-roche-dishes-out-75m-for-relays-shp2-drug-to-pair-with-in-house-program/